tiprankstipranks
Trending News
More News >
Avalo Therapeutics, Inc. (AVTX)
:AVTX
US Market

Avalo Therapeutics (AVTX) Stock Forecast & Price Target

Compare
911 Followers
See the Price Targets and Ratings of:

AVTX Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Avalo
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AVTX Stock 12 Month Forecast

Average Price Target

$32.83
▲(658.20%Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Avalo Therapeutics in the last 3 months. The average price target is $32.83 with a high forecast of $48.00 and a low forecast of $15.00. The average price target represents a 658.20% change from the last price of $4.33.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","26":"$26","49":"$49","14.5":"$14.5","37.5":"$37.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,14.5,26,37.5,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Aug<br/>2024","9":"Dec<br/>2024","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.35,7.707692307692307,11.065384615384616,14.423076923076923,17.78076923076923,21.13846153846154,24.496153846153845,27.853846153846156,31.21153846153846,34.56923076923077,37.92692307692308,41.284615384615385,44.642307692307696,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.35,6.5407692307692304,8.73153846153846,10.92230769230769,13.113076923076921,15.303846153846152,17.49461538461538,19.685384615384613,21.87615384615384,24.066923076923075,26.257692307692302,28.448461538461537,30.639230769230764,{"y":32.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.35,5.169230769230769,5.988461538461538,6.8076923076923075,7.6269230769230765,8.446153846153845,9.265384615384615,10.084615384615384,10.903846153846153,11.723076923076922,12.542307692307691,13.36153846153846,14.180769230769231,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.32,"date":1672531200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.32,"date":1675209600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.32,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.32,"date":1685577600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":17.9,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.61,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.05,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.99,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.96,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.42,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.31,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$48.00Average Price Target$32.83Lowest Price Target$15.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on AVTX
TipRanks AITipRanks
Not Ranked
TipRanks
$4.5
Hold
3.93%
Upside
Reiterated
06/04/25
The overall score is driven by Avalo Therapeutics' significant financial challenges and negative valuation metrics, which are partially offset by positive corporate developments, including strategic management changes and promising product potential. Technical indicators suggest a bearish trend.
H.C. Wainwright Analyst forecast on AVTX
Mitchell KapoorH.C. Wainwright
H.C. Wainwright
$15
Buy
246.42%
Upside
Upgraded
06/02/25
Avalo Therapeutics assumed with a Buy at H.C. WainwrightAvalo Therapeutics assumed with a Buy at H.C. Wainwright
Jefferies Analyst forecast on AVTX
Kambiz YazdiJefferies
Jefferies
$23
Buy
431.18%
Upside
Initiated
03/25/25
Promising Outlook for Avalo Therapeutics' AVTX-009 in HS Treatment
Stifel Nicolaus Analyst forecast on AVTX
Alex Thompson CFAStifel Nicolaus
Stifel Nicolaus
$36
Buy
731.41%
Upside
Initiated
03/25/25
Stifel starts Avalo Therapeutics Inc. (AVTX) at BuyStifel analyst Alex Thompson initiates coverage on Avalo Therapeutics Inc. (NASDAQ: AVTX) with a Buy rating and a price target of $36.00.
Oppenheimer Analyst forecast on AVTX
Leland GershellOppenheimer
Oppenheimer
$35
Buy
708.31%
Upside
Reiterated
03/24/25
Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)
BTIG
$40
Buy
823.79%
Upside
Reiterated
03/20/25
Promising Investment Opportunity in Avalo Therapeutics: Strong Financial Position and Breakthrough HS TreatmentWe view hidradenitis suppurativa (HS) as a high-growth opportunity (US market size is expected to grow from ~$2B/yr today to >$10B/yr by the mid-2030s) where multiple commercially successful therapies can coexist, and we expect AVTX-009 to emerge as the best-in-class IL-1 inhibitor for the disease. Topline results from the ongoing in HS (LOTUS) are expected in 2026 (first patient enrolled October 2024) and we see high odds of AVTX-009's differentiating features (IL-1β potency and specificity, higher potency, better SC bioavailability, and longer half-life) translating into greater efficacy compared to lutikizumab. Beyond HS, mgmt. plans to announce a second indication to evaluate AVTX-009.
Piper Sandler Analyst forecast on AVTX
Yasmeen RahimiPiper Sandler
Piper Sandler
$48
Buy
1008.55%
Upside
Reiterated
03/20/25
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (NASDAQ: AVTX) and Korro Bio (NASDAQ: KRRO)
Wedbush
$18
Buy
315.70%
Upside
Initiated
02/20/25
Avalo Therapeutics initiated with an Outperform at WedbushAvalo Therapeutics initiated with an Outperform at Wedbush
Lucid Capital Analyst forecast on AVTX
Dev PrasadLucid Capital
Lucid Capital
$24
Buy
454.27%
Upside
Initiated
12/17/24
Avalo Therapeutics initiated with a Buy at Lucid CapitalAvalo Therapeutics initiated with a Buy at Lucid Capital
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on AVTX
TipRanks AITipRanks
Not Ranked
TipRanks
$4.5
Hold
3.93%
Upside
Reiterated
06/04/25
The overall score is driven by Avalo Therapeutics' significant financial challenges and negative valuation metrics, which are partially offset by positive corporate developments, including strategic management changes and promising product potential. Technical indicators suggest a bearish trend.
H.C. Wainwright Analyst forecast on AVTX
Mitchell KapoorH.C. Wainwright
H.C. Wainwright
$15
Buy
246.42%
Upside
Upgraded
06/02/25
Avalo Therapeutics assumed with a Buy at H.C. WainwrightAvalo Therapeutics assumed with a Buy at H.C. Wainwright
Jefferies Analyst forecast on AVTX
Kambiz YazdiJefferies
Jefferies
$23
Buy
431.18%
Upside
Initiated
03/25/25
Promising Outlook for Avalo Therapeutics' AVTX-009 in HS Treatment
Stifel Nicolaus Analyst forecast on AVTX
Alex Thompson CFAStifel Nicolaus
Stifel Nicolaus
$36
Buy
731.41%
Upside
Initiated
03/25/25
Stifel starts Avalo Therapeutics Inc. (AVTX) at BuyStifel analyst Alex Thompson initiates coverage on Avalo Therapeutics Inc. (NASDAQ: AVTX) with a Buy rating and a price target of $36.00.
Oppenheimer Analyst forecast on AVTX
Leland GershellOppenheimer
Oppenheimer
$35
Buy
708.31%
Upside
Reiterated
03/24/25
Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)
BTIG
$40
Buy
823.79%
Upside
Reiterated
03/20/25
Promising Investment Opportunity in Avalo Therapeutics: Strong Financial Position and Breakthrough HS TreatmentWe view hidradenitis suppurativa (HS) as a high-growth opportunity (US market size is expected to grow from ~$2B/yr today to >$10B/yr by the mid-2030s) where multiple commercially successful therapies can coexist, and we expect AVTX-009 to emerge as the best-in-class IL-1 inhibitor for the disease. Topline results from the ongoing in HS (LOTUS) are expected in 2026 (first patient enrolled October 2024) and we see high odds of AVTX-009's differentiating features (IL-1β potency and specificity, higher potency, better SC bioavailability, and longer half-life) translating into greater efficacy compared to lutikizumab. Beyond HS, mgmt. plans to announce a second indication to evaluate AVTX-009.
Piper Sandler Analyst forecast on AVTX
Yasmeen RahimiPiper Sandler
Piper Sandler
$48
Buy
1008.55%
Upside
Reiterated
03/20/25
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (NASDAQ: AVTX) and Korro Bio (NASDAQ: KRRO)
Wedbush
$18
Buy
315.70%
Upside
Initiated
02/20/25
Avalo Therapeutics initiated with an Outperform at WedbushAvalo Therapeutics initiated with an Outperform at Wedbush
Lucid Capital Analyst forecast on AVTX
Dev PrasadLucid Capital
Lucid Capital
$24
Buy
454.27%
Upside
Initiated
12/17/24
Avalo Therapeutics initiated with a Buy at Lucid CapitalAvalo Therapeutics initiated with a Buy at Lucid Capital
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avalo Therapeutics

1 Month
xxx
Success Rate
8/19 ratings generated profit
42%
Average Return
+0.72%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.11% of your transactions generating a profit, with an average return of +0.72% per trade.
3 Months
xxx
Success Rate
8/19 ratings generated profit
42%
Average Return
-5.42%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 42.11% of your transactions generating a profit, with an average return of -5.42% per trade.
1 Year
Leland GershellOppenheimer
Success Rate
3/19 ratings generated profit
16%
Average Return
-48.35%
reiterated a buy rating 3 months ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 15.79% of your transactions generating a profit, with an average return of -48.35% per trade.
2 Years
xxx
Success Rate
0/19 ratings generated profit
0%
Average Return
-78.78%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -78.78% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AVTX Analyst Recommendation Trends

Rating
Nov 24
Dec 24
Feb 25
Mar 25
Jun 25
Strong Buy
3
5
6
10
8
Buy
0
0
0
0
0
Hold
2
2
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
7
7
11
9
In the current month, AVTX has received 8 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. AVTX average Analyst price target in the past 3 months is 32.83.
Each month's total comprises the sum of three months' worth of ratings.

AVTX Financial Forecast

AVTX Earnings Forecast

Next quarter’s earnings estimate for AVTX is -$1.40 with a range of -$2.02 to -$1.20. The previous quarter’s EPS was -$1.25. AVTX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year AVTX has Outperformed its overall industry.
Next quarter’s earnings estimate for AVTX is -$1.40 with a range of -$2.02 to -$1.20. The previous quarter’s EPS was -$1.25. AVTX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year AVTX has Outperformed its overall industry.

AVTX Sales Forecast

Next quarter’s sales forecast for AVTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVTX beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year AVTX has Outperformed its overall industry.
Next quarter’s sales forecast for AVTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVTX beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year AVTX has Outperformed its overall industry.

AVTX Stock Forecast FAQ

What is AVTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Avalo Therapeutics, Inc.’s 12-month average price target is 32.83.
    What is AVTX’s upside potential, based on the analysts’ average price target?
    Avalo Therapeutics, Inc. has 658.20% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AVTX a Buy, Sell or Hold?
          Avalo Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Avalo Therapeutics, Inc.’s price target?
            The average price target for Avalo Therapeutics, Inc. is 32.83. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $48.00 ,the lowest forecast is $15.00. The average price target represents 658.20% Increase from the current price of $4.33.
              What do analysts say about Avalo Therapeutics, Inc.?
              Avalo Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of AVTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis